Table 1. Baseline characteristics by race/ethnicity.
|
|
NHW | Black | Hispanic | AAPI | Others | All |
|---|---|---|---|---|---|---|
| (n=736, 53%) | (n=289, 21%) | (n=235, 17%) | (n=45, 3%) | (n=78, 6%) | (n=1383, 100%) | |
| Median age, years* [IQR] | 64 (54–76) | 61 (52–69) | 53 (46–62) | 54 (43–73) | 62 (53–71) | 61 (51–72) |
| Median follow-up, days [IQR] | 90 (30–135) | 90 (30–180) | 90 (30–135) | 42 (21–90) | 70 (30–180) | 90 (30–135) |
| Smoking status | ||||||
| Never | 460 (62%) | 186 (64%) | 180 (77%) | 35 (78%) | 50 (64%) | 911 (66%) |
| Current or former | 261 (35%) | 95 (33%) | 53 (23%) | 8 (18%) | 25 (32%) | 442 (32%) |
| Missing/unknown | 15 (2%) | 8 (3%) | 2 (1%) | 2 (4%) | 3 (4%) | 30 (2%) |
| Obesity | ||||||
| No | 421 (57%) | 133 (46%) | 116 (49%) | 32 (71%) | 45 (58%) | 747 (54%) |
| Yes | 308 (42%) | 156 (54%) | 116 (49%) | 13 (29%) | 33 (42%) | 626 (45%) |
| Missing/unknown | 7 (1%) | 0 (0%) | 3 (1%) | 0 (0%) | 0 (0%) | 10 (1%) |
| Comorbidities† | ||||||
| Cardiovascular | 179 (24%) | 60 (21%) | 14 (6%) | 7 (16%) | 11 (14%) | 271 (20%) |
| Pulmonary | 125 (17%) | 65 (22%) | 33 (14%) | <5 (<11%) | 7 (9%) | 234 (17%) |
| Renal disease | 66 (9%) | 31 (11%) | 13 (6%) | <5 (<11%) | <5 (<6%) | 115 (8%) |
| Diabetes mellitus | 127 (17%) | 98 (34%) | 51 (22%) | 10 (22%) | 20 (26%) | 306 (22%) |
| Missing/unknown | 9 (1%) | 1 (<1%) | 5 (2%) | 0 (0%) | 0 (0%) | 15 (1%) |
| ECOG performance status | ||||||
| 0 | 314 (43%) | 130 (45%) | 123 (52%) | 18 (40%) | 32 (41%) | 617 (45%) |
| 1 | 135 (18%) | 72 (25%) | 48 (20%) | 10 (22%) | 16 (21%) | 281 (20%) |
| 2+ | 69 (9%) | 33 (11%) | 15 (6%) | 5 (11%) | 5 (6%) | 127 (9%) |
| Unknown | 218 (30%) | 53 (18%) | 49 (21%) | 12 (27%) | 25 (32%) | 357 (26%) |
| Missing | 0 (0%) | 1 (<1%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (<1%) |
| Region | ||||||
| Northeast | 247 (34%) | 101 (35%) | 106 (45%) | 12 (27%) | 26 (33%) | 492 (36%) |
| Midwest | 239 (32%) | 110 (38%) | 23 (10%) | 8 (18%) | 12 (15%) | 392 (28%) |
| South | 116 (16%) | 58 (20%) | 27 (11%) | X* | 14 (18%) | 218 (16%) |
| West | 128 (17%) | 16 (6%) | 77 (33%) | 22 (49%) | 24 (31%) | 267 (19%) |
| Undesignated | 6 (1%) | 4 (1%) | 2 (1%) | 3 (7%)* | 2 (3%) | 14 (1%) |
| Month/year of COVID-19 diagnosis | ||||||
| Jan-Apr 2020 | 140 (19%) | 74 (26%) | 41 (17%) | 8 (18%) | 20 (26%) | 283 (20%) |
| May-Aug 2020 | 279 (38%) | 141 (49%) | 101 (43%) | 24 (53%) | 30 (38%) | 575 (42%) |
| Sept-Dec 2020 | 197 (27%) | 42 (15%) | 50 (21%) | 5 (11%) | 16 (21%) | 310 (22%) |
| Jan-Jun 2021 | 118 (16%) | 32 (11%) | 41 (17%) | 7 (16%) | 12 (15%) | 210 (15%) |
| Missing/unknown | 2 (<1%) | 0 (0%) | 2 (1%) | 1 (2%) | 0 (0%) | 5 (<1%) |
| Area of patient residence | ||||||
| Urban | 193 (26%) | 136 (47%) | 124 (53%) | 13 (29%) | 30 (38%) | 496 (36%) |
| Suburban | 315 (43%) | 77 (27%) | 65 (28%) | 17 (38%) | 31 (40%) | 505 (37%) |
| Rural | 81 (11%) | 7 (2%) | 9 (4%) | X* | 0 (0%) | 98 (7%) |
| Missing/unknown | 147 (20%) | 69 (24%) | 37 (16%) | 15 (33%)* | 17 (22%) | 284 (21%) |
| Treatment center characteristics | ||||||
| Academic medical center | 123 (17%) | 102 (35%) | 43 (18%) | 7 (16%) | 11 (14%) | 286 (21%) |
| Community practice | 238 (32%) | 51 (18%) | 44 (19%) | X* | 23 (29%) | 359 (26%) |
| Tertiary care center | 375 (51%) | 136 (47%) | 147 (63%) | 35 (78%) | 44 (56%) | 737 (53%) |
| Missing/unknown | 0 (0%) | 0 (0%) | 1 (<1%) | 3 (7%)* | 0 (0%) | 1 (<1%) |
| Receptor status | ||||||
| HR+/HER2- | 419 (57%) | 135 (47%) | 102 (43%) | 22 (49%) | 43 (55%) | 721 (52%) |
| HR+/HER2+ | 102 (14%) | 35 (12%) | 43 (18%) | 7 (16%) | 9 (12%) | 196 (14%) |
| HR-/HER2+ | 46 (6%) | 28 (10%) | 32 (14%) | X* | X* | 111 (8%) |
| Triple negative | 57 (8%) | 54 (19%) | 35 (15%) | 5 (11%) | 7 (9%) | 158 (11%) |
| Missing/unknown | 112 (15%) | 37 (13%) | 23 (10%) | 11 (24%) | 19 (24%)* | 197 (14%) |
| Cancer status | ||||||
| Remission/NED, >5 years | 247 (34%) | 76 (26%) | 23 (10%) | 9 (20%) | 20 (26%) | 375 (27%) |
| Remission/NED, <5 years | 234 (32%) | 100 (35%) | 77 (33%) | 11 (24%) | 26 (33%) | 448 (32%) |
| Active and responding | 68 (9%) | 35 (12%) | 56 (24%) | X* | 11 (14%) | 173 (13%) |
| Active and stable | 91 (12%) | 28 (10%) | 35 (15%) | 10 (22%) | 5 (6%) | 169 (12%) |
| Active and progressing | 41 (6%) | 27 (9%) | 20 (9%) | 6 (13%) | X* | 97 (7%) |
| Unknown | 48 (7%) | 19 (7%) | 22 (9%) | 6 (13%)* | 15 (19%)* | 104 (8%) |
| Missing | 7 (1%) | 4 (1%) | 2 (1%) | 3 (7%) | 1 (1%) | 17 (1%) |
| Timing of anti-cancer therapy | ||||||
| Never/after COVID-19 | 24 (3%) | 10 (3%) | 7 (3%) | X* | 7 (9%) | 50 (4%) |
| 0–4 weeks | 364 (49%) | 135 (47%) | 158 (67%) | 25 (56%) | 39 (50%) | 721 (52%) |
| 1–3 months | 26 (4%) | 20 (7%) | 19 (8%) | 0 (0%) | X* | 69 (5%) |
| >3 months | 303 (41%) | 118 (41%) | 45 (19%) | 18 (40%) | 24 (31%) | 508 (37%) |
| Missing/unknown | 19 (3%) | 6 (2%) | 6 (3%) | 2 (4%)* | 8 (10%)* | 35 (3%) |
| Modality of active anti-cancer therapy‡, § | ||||||
| None | 333 (45%) | 127 (44%) | 53 (23%) | 20 (44%) | 30 (38%) | 563 (41%) |
| Chemotherapy | 117 (16%) | 68 (24%) | 88 (37%) | 11 (24%) | 14 (18%) | 298 (22%) |
| Targeted therapy | 112 (15%) | 38 (13%) | 59 (25%) | 8 (18%) | 11 (14%) | 228 (16%) |
| Anti-HER2 therapy | 60 (8%) | 17 (6%) | 36 (15%) | <5 (<11%) | <5 (<6%) | 123 (9%) |
| CDK4/6 inhibitor | 33 (4%) | 12 (4%) | 14 (6%) | <5 (<11%) | <5 (<6%) | 65 (5%) |
| Other¶ | 14 (2%) | 5 (2%) | <5 (<2%) | <5 (<11%) | 0 (0%) | 24 (2%) |
| Endocrine therapy | 283 (38%) | 86 (30%) | 91 (39%) | 15 (33%) | 26 (33%) | 501 (36%) |
| Immunotherapy | 12 (2%) | 8 (3%) | <5 (<2%) | <5 (<11%) | <5 (<6%) | 28 (2%) |
| Local (surgery/radiation) | 80 (11%) | 37 (13%) | 41 (17%) | <5 (<11%) | 9 (12%) | 172 (12%) |
| Other | 13 (2%) | 3 (1%) | 2 (1%) | 0 (0%) | 0 (0%) | 18 (1%) |
| Missing/unknown | 12 (2%) | 7 (2%) | 5 (2%) | 0 (0%) | 5 (6%) | 29 (2%) |
| Severity of COVID-19 | ||||||
| Mild | 535 (73%) | 177 (61%) | 173 (74%) | 28 (62%) | 50 (64%) | 963 (70%) |
| Moderate | 174 (24%) | 97 (34%) | 56 (24%) | 14 (31%) | 21 (27%) | 362 (26%) |
| Severe | 25 (3%) | 15 (5%) | 6 (3%) | X* | 7 (9%) | 56 (4%) |
| Missing/unknown | 2 (<1%) | 0 (0%) | 0 (0%) | 3 (7%)* | 0 (0%) | 2 (<1%) |
Variable categories with one to five cases are masked by replacing with N < 5 according to CCC19 policy.
*
Cells combined to mask N<5 according to CCC19 low count policy.
†
Age was truncated at 90.
‡
Percentages could sum to >100% because categories are not mutually exclusive.
§
Within 3 months of COVID-19 diagnosis.
¶
Therapies other than anti-Her2 therapy or CDK4/6 inhibitor.